

University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln

Uniformed Services University of the Health
Sciences

U.S. Department of Defense

2011

ACR Appropriateness Criteria[®] on Cerebrovascular Disease

Robert L. DeLaPaz

Columbia University Medical Center, rld17@columbia.edu

Franz J. Wippold II

Mallinckrodt Institute of Radiology

Rebecca S. Cornelius

University of Cincinnati

Sepideh Amin-Hanjani

University of Illinois College of Medicine

Edgardo J. Angtuaco

University of Arkansas for Medical Sciences

See next page for additional authors

Follow this and additional works at: <https://digitalcommons.unl.edu/usuhs>



Part of the [Medicine and Health Sciences Commons](#)

DeLaPaz, Robert L.; Wippold, Franz J. II; Cornelius, Rebecca S.; Amin-Hanjani, Sepideh; Angtuaco, Edgardo J.; Broderick, Daniel F.; Brown, Douglas C.; Creasy, Jeffrey L.; Davis, Patricia C.; Garvin, Charles F.; Hoh, Brian L.; McConnell, Charles T. Jr; Mechtler, Laszlo L.; Seidenwurm, David J.; Smirniotopoulos, James G.; Tobben, Paul J.; Waxman, Alan D.; and Zipfel, Greg J., "ACR Appropriateness Criteria[®] on Cerebrovascular Disease" (2011). *Uniformed Services University of the Health Sciences*. 61.
<https://digitalcommons.unl.edu/usuhs/61>

This Article is brought to you for free and open access by the U.S. Department of Defense at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Uniformed Services University of the Health Sciences by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Robert L. DeLaPaz, Franz J. Wippold II, Rebecca S. Cornelius, Sepideh Amin-Hanjani, Edgardo J. Angtuaco, Daniel F. Broderick, Douglas C. Brown, Jeffrey L. Creasy, Patricia C. Davis, Charles F. Garvin, Brian L. Hoh, Charles T. McConnell Jr, Laszlo L. Mechtler, David J. Seidenwurm, James G. Smirniotopoulos, Paul J. Tobben, Alan D. Waxman, and Greg J. Zipfel

ACR Appropriateness Criteria[®] on Cerebrovascular Disease

Robert L. DeLaPaz, MD^a, Franz J. Wippold II, MD^b, Rebecca S. Cornelius, MD^c,
Sepideh Amin-Hanjani, MD^{d,e,f}, Edgardo J. Angtuaco, MD^g,
Daniel F. Broderick, MD^h, Douglas C. Brown, MDⁱ, Jeffrey L. Creasy, MD^j,
Patricia C. Davis, MD^k, Charles F. Garvin, MD^l, Brian L. Hoh, MD^{e,f,m},
Charles T. McConnell Jr, MDⁿ, Laszlo L. Mechtler, MD^{o,p},
David J. Seidenwurm, MD^q, James G. Smirniotopoulos, MD^r, Paul J. Tobben, MD^s,
Alan D. Waxman, MD^{t,u}, and Greg J. Zipfel, MD^{e,f,v}

Stroke is the sudden onset of focal neurologic symptoms due to ischemia or hemorrhage in the brain. Current FDA-approved clinical treatment of acute ischemic stroke involves the use of the intravenous thrombolytic agent recombinant tissue plasminogen activator given <3 hours after symptom onset, following the exclusion of intracerebral hemorrhage by a noncontrast CT scan. Advanced MRI, CT, and other techniques may confirm the stroke diagnosis and subtype, demonstrate lesion location, identify vascular occlusion, and guide other management decisions but, within the first 3 hours after ictus, should not delay or be used to withhold recombinant tissue plasminogen activator therapy after the exclusion of acute hemorrhage on noncontrast CT scans. MR diffusion-weighted imaging is highly sensitive and specific for acute cerebral ischemia and, when combined with perfusion-weighted imaging, may be used to identify potentially salvageable ischemic tissue, especially in the period >3 hours after symptom onset. Advanced CT perfusion methods improve sensitivity to acute ischemia and are increasingly used with CT angiography to evaluate acute stroke as a supplement to noncontrast CT. The ACR Appropriateness Criteria[®] are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Key Words: Appropriateness Criteria[®], stroke, transient ischemic attack, TIA, thrombolysis, hemorrhage, aneurysm

J Am Coll Radiol 2011;8:532-538. Copyright © 2011 American College of Radiology

^aColumbia University Medical Center, New York, New York.

^bMallinckrodt Institute of Radiology, St Louis, Missouri.

^cUniversity of Cincinnati, Cincinnati, Ohio.

^dUniversity of Illinois College of Medicine, Chicago, Illinois.

^eAmerican Association of Neurological Surgeons, Rolling Meadows, Illinois.

^fCongress of Neurological Surgeons, Schaumburg, Illinois.

^gUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas.

^hMayo Clinic Jacksonville, Jacksonville, Florida.

ⁱHampton Roads Radiology Associates, Norfolk, Virginia.

^jVanderbilt University, Nashville, Tennessee.

^kNorthwest Radiology Consultants, Atlanta, Georgia.

^lSt Luke's Center for Diagnostic Imaging, Chesterfield, Missouri.

^mUniversity of Florida, Gainesville, Florida.

ⁿGood Samaritan Hospital, Cincinnati, Ohio.

^oDent Neurologic Institute, Amherst, New York.

^pAmerican Academy of Neurology, St Paul, Minnesota.

^qRadiological Associates of Sacramento, Sacramento, California.

^rUniformed Services University of the Health Sciences, Bethesda, Maryland.

^sPresbyterian Hospital, Charlotte, North Carolina.

^tCedars-Sinai Medical Center, Los Angeles, California.

^uSociety of Nuclear Medicine, Reston, Virginia.

^vWashington University School of Medicine, St Louis, Missouri.

Corresponding author and reprints: Robert L. DeLaPaz, MD, American College of Radiology, 1891 Preston White Drive, Reston, VA 20191; e-mail: rl17@columbia.edu.

The ACR seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria[®] through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply society endorsement of the final document.

This article is a revised version of the ACR Appropriateness Criteria[®] on Cerebrovascular Disease. Practitioners are encouraged to refer to the complete version at <http://www.acr.org/ac>.

SUMMARY OF LITERATURE REVIEW

Introduction/Background

Diseases of the cerebral vasculature are often manifested as stroke, a generic term encompassing a range of ischemic and hemorrhagic lesions. There are approximately 795,000 new (610,000) or recurrent (185,000) strokes per year in the United States, an average of 1 every 40 seconds [1]. Stroke is the third leading underlying or contributing cause of death in the United States, behind heart disease and cancer, accounting for 1 in every 18 (137,265) deaths in 2006, an average of 1 death every 3 to 4 minutes [1]. Of all strokes, 87% are ischemic, 10% are intracerebral hemorrhages, and 3% are subarachnoid hemorrhages [1]. Significant functional disability is common in nonfatal cases, and stroke is a leading cause of serious, long-term disability in the United States [1]. The estimated direct and indirect cost of stroke in the United States in 2009 was \$68.9 billion [1].

Imaging and Stroke Risk

Because of the gravity of stroke's sequelae, considerable effort has been expended to identify risk factors for the disease and strategies for stroke prevention in high-risk patients [2]. Although the diagnostic accuracies of duplex ultrasound, CT angiography (CTA), MR angiography (MRA) and time-resolved contrast-enhanced MRA are all high for internal carotid artery stenosis (70% to 99%) [3,4], only ultrasound seems to offer cost-effective initial screening. Combined use of ultrasound and contrast-enhanced MRA is an increasingly common practice [5-9].

Multislice CTA is promising, but relatively few rigorous studies have been done, and the technique remains limited by the large intravenous (IV) contrast injection volumes required, the potential contrast toxicity or reaction, the radiation dose, and the plaque calcification that may obscure the stenosis [4,10,11]. The predictive value of carotid stenosis for symptomatic cerebral ischemia may be further improved by direct characterization of the atherosclerotic plaque [12,13].

Elevated ischemic stroke risk in patients with chronic carotid stenosis or occlusion can also be identified by using single photon-emission CT and research xenon CT methods, which show reduced cerebral vascular reserve after acetazolamide challenge, or by elevated oxygen extraction fraction using ^{15}O PET [14-16]. Although there is limited experience with MR and CT perfusion methods for this purpose, elevated cerebral blood volume seems to correlate with reduced cerebral vascular reserve and increased stroke risk [17,18], and these modalities are more widely available than PET.

Clinical Characteristics of Stroke

Clinically, stroke is most often characterized by the ictal onset of focal neurologic symptoms due to ischemia or hemorrhage into the brain. Ischemic infarc-

tion can be classified into various subgroups on the basis of the mechanism of the ischemia (hemodynamic or thromboembolic) and the pathology of the vascular lesion: atherosclerotic, lacunar, cardioembolic, or indeterminate.

Thrombolytic Treatment

Current clinical practice in the United States is based on the 1996 FDA approval of the thrombolytic agent recombinant tissue plasminogen activator (rtPA) given intravenously, preferably <1 hour and no later than 3 hours after symptom onset, after the exclusion of intracerebral hemorrhage by a noncontrast CT (NCCT) scan [19]. The Joint Commission has included these criteria in its requirements for stroke center designation [20]. Recommendations also include the performance of NCCT within 25 minutes of admission and expert interpretation within 20 minutes (45-minute "door-to-interpretation" time) [21]. Recent increases in public awareness, emergency medical response, and the establishment of dedicated stroke centers have resulted in 19% to 60% of admissions arriving at treatment centers <3 hours after symptom onset. However, after appropriate medical exclusions, successful treatment with rtPA, without symptomatic major hemorrhage, is limited to 3% to 8.5% of ischemic stroke admissions [21-24].

Transient Ischemic Attack

Traditionally, if focal neurologic symptoms continued for >24 hours, stroke was diagnosed; otherwise, a focal neurologic deficit lasting <24 hours was defined as a transient ischemic attack (TIA). However, this time-based definition of TIA may be inadequate and misleading, potentially leading to inappropriate delays in diagnosis and treatment. A "tissue-based" definition has been proposed that considers all acute focal neurologic deficits as possible infarcts and classifies them as "acute neurovascular syndromes" or "acute ischemic cerebrovascular syndromes" on the basis of the degree of certainty of tissue ischemic injury, which is determined primarily by tissue and vascular imaging studies [25-27]. Because most transient ischemic neurologic symptoms (70%) last for ≤ 2 hours and 30% to 50% show tissue injury on MR diffusion-weighted imaging (DWI) [26,28,29], the American Stroke Association recently proposed a new definition of TIA as "a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction" [25,28]. This change reflects the growing emphasis on the earliest possible diagnosis and treatment of acute ischemia and the use of NCCT for exclusion of hemorrhage and MRI for definitive infarct diagnosis [21,28].

MRI

Rapid and accurate diagnosis of ischemia, completed infarction, and hemorrhage has become paramount in im-

portance for treating acute cerebrovascular disease because of the demonstrable benefit (and hemorrhage risk) of acute IV and intra-arterial thrombolytic therapy for cerebral ischemia in prospective clinical trials [22-24,30-37]. MRI in the form of DWI has been shown to be exquisitely sensitive to acute infarction within minutes of the precipitating ictus, with sensitivity of 88% to 100% compared to NCCT's mean sensitivity of 66% (range, 20%-87%) [38-41]. The specificity of DWI for ischemic injury is also high (95%-100%), although small reductions in apparent diffusion coefficient (eg, 20% below normal) can represent reversible ischemia that may not progress to completed infarct [42]. Additional information obtainable through the combined use of dynamic cerebral blood volume techniques (perfusion-weighted imaging [PWI] as well as vascular imaging [MRA]) makes MRI an appealing tool for diagnosis and treatment monitoring of acute cerebrovascular disease [41-45].

However, enthusiasm for MRI in the setting of acute stroke has been tempered by the variable and confounding appearance of hemorrhage. Recent experience using T2* (gradient-echo) imaging to detect low-signal parenchymal hemorrhage and fluid-attenuated inversion recovery scans to detect high-signal subarachnoid blood (subarachnoid hemorrhage) have helped renew interest in MRI as a first-line modality in patients with acute, focal neurologic deficits [46-48]. However, there is currently insufficiently widespread clinical experience to recommend MRI over CT for routine exclusion of parenchymal hemorrhage or to withhold rtPA therapy in the presence of microhemorrhages on MRI within the first 3 hours after ictus [21,47].

Because of the small percentage of patients with acute stroke treated within the 3-hour limit, there is growing interest in expanding the treatment window without increasing hemorrhage risk. A pooled risk-benefit analysis of existing rtPA trials using NCCT scan exclusion of hemorrhage has suggested that treatment may be safe in some patients out to 4.5 hours after ictus [22,32], but FDA and American Stroke Association recommendations have not yet been modified to include this expanded treatment window in published guidelines. In addition, several current clinical trials are focused on the use of thrombolytic and neuroprotective agents combined with MRI techniques to expand the treatment window by identifying the "ischemic penumbra," the underperfused yet viable halo of brain parenchyma around or interspersed with the region of completed infarction that is at risk for progressing to infarction. Gadolinium bolus dynamic susceptibility contrast MR PWI measures tissue blood flow parameters (cerebral blood flow, cerebral blood volume, mean transit time, and time to peak) on the basis of the central volume principle and is being used to identify the volume of tissue with reduced blood flow, which is then compared with the vol-

ume of presumed infarcted tissue as indicated by restricted diffusion (reduced apparent diffusion coefficient on DWI). When the low-blood flow tissue volume is larger than the restricted diffusion volume by $\geq 20\%$, a perfusion-diffusion (PWI-DWI) "mismatch" is said to exist as an indicator of potentially salvageable tissue. Imaging of oxygen metabolism may further define potentially salvageable tissue within this mismatch zone by demonstrating regions of elevated oxygen extraction fraction in stage II "misery perfusion," including DWI-positive (restricted diffusion) regions [14,49,50]. Images of oxygen metabolism can be acquired using ^{15}O PET or experimental MRI methods, and images of hypoxic tissue can be obtained with ^{18}F fluoromisonidazole PET, but these imaging techniques are not currently available in general clinical practice [50-52]. Currently, there is insufficient scientific evidence or widespread clinical experience to recommend these diagnostic approaches for routine thrombolytic treatment beyond the 3-hour window after symptom onset [53].

CT

On the basis of ready availability and high sensitivity to the presence or absence of acute blood, NCCT historically has been the preferred modality for initial imaging of suspected stroke but has lacked a similar sensitivity to acute ischemia and infarction. The relatively low sensitivity of NCCT to early ischemic injury (only one-third to two-thirds of lesions detected in various studies) and the variable quantitation and interpretation of ischemic changes have limited their use in early stroke management.

A recent resurgence in the use of CT for initial stroke evaluation has occurred with the increasing clinical availability of CT perfusion and CTA. CT perfusion is acquired by rapid scanning during a bolus IV contrast infusion, and blood flow parameters (cerebral blood flow, cerebral blood volume, mean transit time, and time to peak) are calculated on the basis of the central volume principle. This has transformed CT into a technique with high sensitivity to cerebrovascular abnormalities and early perfusion deficits, detectable before observable low-density changes on NCCT [39,54]. Quantitative CT perfusion measurements of cerebral blood flow parameters have been proposed as a means of discriminating between infarct and penumbra and have been compared favorably with MRI [55-61]. These measurements, plus the ability to quickly identify acute hemorrhage and vascular occlusive lesions as well as the ubiquitous availability of CT scanners, have been suggested as the key advantages of CT over MRI for acute stroke evaluation. However, greater risks of renal toxicity, contrast reaction, or fluid overload from iodinated contrast materials vs gadolinium, the variability in CT perfusion quantitative methods [61], and the lack of a direct measure of cellular

viability such as diffusion restriction mitigate these advantages over MRI [62].

Acute Stroke and Advanced Imaging

It should be emphasized that the current FDA-approved treatment for acute ischemic stroke symptoms is IV rtPA within 3 hours of symptom onset and that the recommended imaging study is NCCT to exclude acute hemorrhage. The multimodality MRI and CT studies described above may be useful to confirm the stroke diagnosis and subtype, demonstrate lesion location, identify vascular occlusion, and guide other management decisions within and beyond the 3-hour period. But the American Stroke Association guidelines and others specifically recommend that emergency IV rtPA treatment within the first 3 hours after ictus not be delayed in order to obtain multimodality imaging studies and that treatment not be withheld on the basis of either positive or negative MRI or CT findings, other than acute hemorrhage on NCCT [47,53,60,63-65].

A more complete literature review is available at http://www.acr.org/SecondaryMainMenuCategories/quality_safety/

[app_criteria/pdf/ExpertPanelonNeurologicImaging/CerebrovascularDiseaseDoc2.aspx](http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonNeurologicImaging/CerebrovascularDiseaseDoc2.aspx) (see Variant 1).

Assumptions

All patient scenarios should be addressed as though the patient had been referred for imaging after a history and physical examination that include neurologic, vascular, and ophthalmoscopic examinations.

ANTICIPATED EXCEPTIONS

Nephrogenic systemic fibrosis is a disorder with a scleroderma-like presentation and a spectrum of manifestations that can range from limited clinical sequelae to fatality. It seems to be related to both underlying severe renal dysfunction and the administration of gadolinium-based contrast agents. It has occurred primarily in patients on dialysis, rarely in patients with very limited glomerular filtration rates (ie, <30 mL/min/1.73 m²), and almost never in other patients. There is growing literature regarding nephrogenic systemic fibrosis. Although some controversy and lack of clarity remain, there is a consensus that it is advisable to avoid all gadolinium-based contrast agents in dialysis-dependent patients unless the possible benefits clearly outweigh the

Variant 1. New focal neurologic defect, fixed or worsening; <3 hours

Radiologic Procedure	Rating	Comments	RRL
CT head without contrast	9	Noncontrast head CT, to exclude acute intracranial hemorrhage, is needed prior to rtPA thrombolytic therapy. Delaying or withholding rtPA thrombolysis in the 3-hour window after symptom onset on the basis of multimodality MRI (DWI, PWI, GRE, or MRA) or CT (CTP or CTA) may not be medically appropriate.*	☢☢☢
MRI head with or without contrast	8	Consider DSC PWI if stenosis found. MRI with DWI preferred if thrombolytic treatment not delayed or withheld.†	0
MRA head and neck with or without contrast	8	Combined vascular and cerebral evaluation should be considered.†	0
CT head with contrast	8	Combined vascular and cerebral evaluation should be considered.*	☢☢☢
CTA head and neck with contrast	8	Combined vascular and cerebral evaluation should be considered.*	☢☢☢
CT perfusion head	6	In this scenario, CTP and CTA are equally useful and can be obtained together (with two injections on most scanners or one injection on volume CT) (but should not delay rtPA therapy decision).*	☢☢☢
Arteriography neck	5	If intra-arterial therapy is considered.	☢☢☢
Arteriography cervicocerebral	5	If intra-arterial therapy is considered.	☢☢☢
Ultrasound carotid with Doppler	2		0
Ultrasound transcranial with Doppler	2		0
MRI functional head	1		0
MRI spectroscopy head	1		0
¹⁵ O PET head	1		☢☢☢
^{99m} Tc HMPAO SPECT head	1		☢☢☢

Note: Rating scale: 1, 2, and 3 = usually not appropriate; 4, 5, and 6 = may be appropriate; 7, 8, and 9 = usually appropriate. Variant tables addressing 10 additional cerebrovascular disease scenarios are available at http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonNeurologicImaging/CerebrovascularDiseaseDoc2.aspx. CTA = CT angiography; CTP = CT perfusion; DSC = dynamic susceptibility contrast; DWI = diffusion-weighted imaging; GRE = gradient echo; HMPAO = hexamethylpropyleneamine oxime; MRA = MR angiography; PWI = perfusion-weighted imaging; RRL = relative radiation level; rtPA = recombinant tissue plasminogen activator; SPECT = single photon-emission CT.

*See text under "Relative Radiation Level Information" for important radiation dose warnings with multiple or repeated CT procedures.

†See statement regarding contrast in text under "Anticipated Exceptions."

Table 1. Relative radiation level designations

Relative Radiation Level	Adult Effective Dose Estimate Range (mSv)	Pediatric Effective Dose Estimate Range (mSv)
0	0	0
☼	<0.1	<0.03
☼☼	0.1-1	0.03-0.3
☼☼☼	1-10	0.3-3
☼☼☼☼	10-30	3-10
☼☼☼☼☼	30-100	10-30

Note: Relative radiation level assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The relative radiation levels for these examinations are designated as not specified.

risk and to limit the type and amount in patients with estimated glomerular filtration rates < 30 mL/min/1.73 m². For more information, please see the ACR's *Manual on Contrast Media* [66].

RELATIVE RADIATION LEVEL INFORMATION

CT stroke protocols combining brain NCCT, CTA, and CT perfusion may produce a relative radiation level (RRL) of ☼☼☼, and repeated use of this protocol in an individual patient may result in high radiation exposure (eg, RRL of ☼☼☼☼) to the scalp and eyes.

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, an RRL indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower compared with those specified for adults (Table 1). Additional information regarding radiation dose assessment for imaging examinations can be found in *ACR Appropriateness Criteria®: Radiation Dose Assessment Introduction* [67].

REFERENCES

- Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2009;119:480-6.
- Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation* 2006;113:e873-923.
- Mathiesen EB, Joakimsen O, Bonna KH. Intersonographer reproducibility and intermethod variability of ultrasound measurements of carotid artery stenosis: the Tromsø Study. *Cerebrovasc Dis* 2000;10:207-13.
- Wardlaw JM, Chappell FM, Best JJ, Wartolowska K, Berry E. Non-invasive imaging compared with intra-arterial angiography in the diagnosis of symptomatic carotid stenosis: a meta-analysis. *Lancet* 2006;367:1503-12.
- Barth A, Arnold M, Mattle HP, Schroth G, Remonda L. Contrast-enhanced 3-D MRA in decision making for carotid endarterectomy: a 6-year experience. *Cerebrovasc Dis* 2006;21:393-400.
- Derdeyn CP, Powers WJ. Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease. *Stroke* 1996;27:1944-50.
- Honish C, Sadanand V, Fladeland D, Chow V, Pirouzmand F. The reliability of ultrasound measurements of carotid stenosis compared to MRA and DSA. *Can J Neurol Sci* 2005;32:465-71.
- Obuchowski NA, Modic MT, Magdinec M, Masaryk TJ. Assessment of the efficacy of noninvasive screening for patients with asymptomatic neck bruits. *Stroke* 1997;28:1330-9.
- U-King-Im JM, Hollingworth W, Trivedi RA, et al. Cost-effectiveness of diagnostic strategies prior to carotid endarterectomy. *Ann Neurol* 2005;58:506-15.
- Bartlett ES, Walters TD, Symons SP, Fox AJ. Quantification of carotid stenosis on CT angiography. *AJNR Am J Neuroradiol* 2006;27:13-9.
- Koelmay MJ, Nederkoorn PJ, Reitsma JB, Majoie CB. Systematic review of computed tomographic angiography for assessment of carotid artery disease. *Stroke* 2004;35:2306-12.
- U-King-Im JM, Tang TY, Patterson A, et al. Characterisation of carotid atheroma in symptomatic and asymptomatic patients using high resolution MRI. *J Neurol Neurosurg Psychiatry* 2008;79:905-12.
- Wintermark M, Jawadi SS, Rapp JH, et al. High-resolution CT imaging of carotid artery atherosclerotic plaques. *AJNR Am J Neuroradiol* 2008;29:875-82.
- Derdeyn CP, Videen TO, Yundt KD, et al. Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited. *Brain* 2002;125:595-607.
- Kuroda S, Shiga T, Houkin K, et al. Cerebral oxygen metabolism and neuronal integrity in patients with impaired vasoreactivity attributable to occlusive carotid artery disease. *Stroke* 2006;37:393-8.
- Nemoto EM, Yonas H, Kuwabara H, et al. Identification of hemodynamic compromise by cerebrovascular reserve and oxygen extraction fraction in occlusive vascular disease. *J Cereb Blood Flow Metab* 2004;24:1081-9.
- Endo H, Inoue T, Ogasawara K, Fukuda T, Kanbara Y, Ogawa A. Quantitative assessment of cerebral hemodynamics using perfusion-weighted MRI in patients with major cerebral artery occlusive disease: comparison with positron emission tomography. *Stroke* 2006;37:388-92.
- Furukawa M, Kashiwagi S, Matsunaga N, Suzuki M, Kishimoto K, Shirao S. Evaluation of cerebral perfusion parameters measured by perfusion CT in chronic cerebral ischemia: comparison with xenon CT. *J Comput Assist Tomogr* 2002;26:272-8.
- Genentech. Full prescribing information: Activase® (alteplase). Available at: <http://www.gene.com/gene/products/information/cardiovascular/activase/insert.jsp>. Accessed June 24, 2011.
- Joint Commission. Disease-specific care (DSC) certification. Stroke performance measurement implementation guide. 2nd ed, version 2.a. Available at: http://www.jointcommission.org/assets/1/18/stroke_pm_implementation_guide_ver_2a.pdf. Accessed June 24, 2011.
- Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. *Stroke* 2005;36:916-23.

22. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. *Lancet* 2004;363:768-74.
23. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. *Stroke* 2003;34:799-800.
24. Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. *Stroke* 2005;36:1232-40.
25. Albers GW. Acute cerebrovascular syndrome: time for new terminology for acute brain ischemia. *Nat Clin Pract Cardiovasc Med* 2006;3:521.
26. Kidwell CS, Warach S. Acute ischemic cerebrovascular syndrome: diagnostic criteria. *Stroke* 2003;34:2995-8.
27. Warach S, Kidwell CS. The redefinition of TIA: the uses and limitations of DWI in acute ischemic cerebrovascular syndromes. *Neurology* 2004;62:359-60.
28. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. *Stroke* 2009;40:2276-93.
29. Restrepo L, Jacobs MA, Barker PB, Wityk RJ. Assessment of transient ischemic attack with diffusion- and perfusion-weighted imaging. *AJNR Am J Neuroradiol* 2004;25:1645-52.
30. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* 1995;333:1581-7.
31. Donnan GA, Baron JC, Ma H, Davis SM. Penumbra selection of patients for trials of acute stroke therapy. *Lancet Neurol* 2009;8:261-9.
32. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med* 2008;359:1317-29.
33. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC. Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? *Neurology* 2003;61:71-5.
34. Khatri P, Hill MD, Palesch YY, et al. Methodology of the Interventional Management of Stroke III Trial. *Int J Stroke* 2008;3:130-7.
35. Mattle HP, Arnold M, Georgiadis D, et al. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. *Stroke* 2008;39:379-83.
36. Mielke O, Wardlaw J, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. *Cochrane Database Syst Rev* 2004;CD000514.
37. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. *Stroke* 2008;39:1205-12.
38. Baird AE, Warach S. Magnetic resonance imaging of acute stroke. *J Cereb Blood Flow Metab* 1998;18:583-609.
39. Coutts SB, Lev MH, Eliasziw M, et al. ASPECTS on CTA source images versus unenhanced CT: added value in predicting final infarct extent and clinical outcome. *Stroke* 2004;35:2472-6.
40. Gonzalez RG, Schaefer PW, Buonanno FS, et al. Diffusion-weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. *Radiology* 1999;210:155-62.
41. Sorensen AG, Copen WA, Ostergaard L, et al. Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean tissue transit time. *Radiology* 1999;210:519-27.
42. Fiehler J, Knudsen K, Kucinski T, et al. Predictors of apparent diffusion coefficient normalization in stroke patients. *Stroke* 2004;35:514-9.
43. Ay H, Buonanno FS, Rordorf G, et al. Normal diffusion-weighted MRI during stroke-like deficits. *Neurology* 1999;52:1784-92.
44. Fisher M, Albers GW. Applications of diffusion-perfusion magnetic resonance imaging in acute ischemic stroke. *Neurology* 1999;52:1750-6.
45. Marks MP, Tong DC, Beaulieu C, Albers GW, de Crespigny A, Moseley ME. Evaluation of early reperfusion and i.v. tPA therapy using diffusion- and perfusion-weighted MRI. *Neurology* 1999;52:1792-8.
46. Fiebach JB, Schellinger PD, Gass A, et al. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. *Stroke* 2004;35:502-6.
47. Fiehler J, Albers GW, Boulanger JM, et al. Bleeding Risk Analysis in Stroke Imaging Before Thrombolysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. *Stroke* 2007;38:2738-44.
48. Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. *JAMA* 2004;292:1823-30.
49. Hjort N, Butcher K, Davis SM, et al. Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. *Stroke* 2005;36:388-97.
50. Sobesky J, Zaro Weber O, Lehnhardt FG, et al. Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke. *Stroke* 2005;36:980-5.
51. Lee JM, Vo KD, An H, et al. Magnetic resonance cerebral metabolic rate of oxygen utilization in hyperacute stroke patients. *Ann Neurol* 2003;53:227-32.
52. Takasawa M, Moustafa RR, Baron JC. Applications of nitroimidazole in vivo hypoxia imaging in ischemic stroke. *Stroke* 2008;39:1629-37.
53. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. *Stroke* 2007;38:1655-711.
54. Smith WS, Roberts HC, Chuang NA, et al. Safety and feasibility of a CT protocol for acute stroke: combined CT, CT angiography, and CT perfusion imaging in 53 consecutive patients. *AJNR Am J Neuroradiol* 2003;24:688-90.
55. Mullins ME, Schaefer PW, Sorensen AG, et al. CT and conventional and diffusion-weighted MR imaging in acute stroke: study in 691 patients at presentation to the emergency department. *Radiology* 2002;224:353-60.
56. Parsons MW, Pepper EM, Chan V, et al. Perfusion computed tomography: prediction of final infarct extent and stroke outcome. *Ann Neurol* 2005;58:672-9.
57. Saur D, Kucinski T, Grzyska U, et al. Sensitivity and interrater agreement of CT and diffusion-weighted MR imaging in hyperacute stroke. *AJNR Am J Neuroradiol* 2003;24:878-85.
58. Schaefer PW, Roccatagliata L, Ledezma C, et al. First-pass quantitative CT perfusion identifies thresholds for salvageable penumbra in acute stroke patients treated with intra-arterial therapy. *AJNR Am J Neuroradiol* 2006;27:20-5.
59. Wintermark M, Flanders AE, Velthuis B, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. *Stroke* 2006;37:979-85.
60. Wintermark M, Rowley HA, Lev MH. Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro CT. *Radiology* 2009;251:619-26.
61. Wintermark M, Meuli R, Browaeys P, et al. Comparison of CT perfusion and angiography and MRI in selecting stroke patients for acute treatment. *Neurology* 2007;68:694-7.

62. Latchaw RE, Yonas H, Hunter GJ, et al. Guidelines and recommendations for perfusion imaging in cerebral ischemia: a scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. *Stroke* 2003;34:1084-104.
63. De Keyser J, Gdovinova Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. *Stroke* 2007;38:2612-8.
64. Kohrmann M, Schellinger PD. Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro MR imaging. *Radiology* 2009;251:627-33.
65. Wardlaw JM, Mielke O. Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment—systematic review. *Radiology* 2005;235:444-53.
66. American College of Radiology. Manual on contrast media v7. Available at: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx.
67. American College of Radiology. ACR Appropriateness Criteria®: radiation dose assessment introduction. Available at: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/RRLInformation.aspx. Accessed May 23, 2011.